Last reviewed · How we verify
Control Vaccine Typbar TCV®
Typbar TCV is a conjugate vaccine that stimulates immune response against Salmonella typhi by presenting purified polysaccharide antigens conjugated to a carrier protein.
Typbar TCV is a conjugate vaccine that stimulates immune response against Salmonella typhi by presenting purified polysaccharide antigens conjugated to a carrier protein. Used for Prevention of typhoid fever caused by Salmonella typhi.
At a glance
| Generic name | Control Vaccine Typbar TCV® |
|---|---|
| Also known as | Typbar TCV® |
| Sponsor | International Vaccine Institute |
| Drug class | Conjugate vaccine |
| Target | Salmonella typhi Vi polysaccharide antigen |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains the Vi polysaccharide capsular antigen of Salmonella typhi conjugated to tetanus toxoid, which enhances immunogenicity and promotes both T-cell and B-cell responses. This conjugate design improves antibody production and immunological memory compared to unconjugated polysaccharide vaccines, providing protection against typhoid fever infection.
Approved indications
- Prevention of typhoid fever caused by Salmonella typhi
Common side effects
- Injection site pain or erythema
- Fever
- Headache
- Myalgia
Key clinical trials
- Opportunistic Pneumococcal Immunisation Trial in MALnutrition (PHASE4)
- Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh (PHASE1, PHASE2)
- Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Control Vaccine Typbar TCV® CI brief — competitive landscape report
- Control Vaccine Typbar TCV® updates RSS · CI watch RSS
- International Vaccine Institute portfolio CI